Skovgaard
Jonas Skovgaard, Aarhus C DK
Patent application number | Description | Published |
---|---|---|
20150044260 | NANOPARTICLE AGGREGATES CONTAINING OSTEOPONTIN AND CALCIUM- AND/OR STRONTIUM-CONTAINING PARTICLES - The present invention relates to nanoparticle aggregates comprising osteopontin (OPN) and one or more particles containing calcium and/or strontium and to their use for reducing or preventing biofilm growth or for removing biofilm. The invention furthermore relates to the use of the nanoparticle aggregates for treating, alleviating or preventing biofilm-related diseases. | 02-12-2015 |
Jørn Skovgaard, Smorum DK
Patent application number | Description | Published |
---|---|---|
20120263329 | HEARING DEVICE WITH AUTOMATIC CLIPPING PREVENTION AND CORRESPONDING METHOD - In digital hearing devices, it is common to reduce the preamplifier gain when very loud signals are received in order to avoid clipping. It is known to temporarily reduce the preamplifier gain with fast attack and release times when a clipping of the input signal in the digitiser is expected. Perceived signal quality of the audible signal provided to the user of the hearing device is herein improved by simultaneously providing relatively fast and relatively slow temporary reductions of the amplifier gain such that the slow gain reductions reduce the occurrences of fast gain reductions. This allows the hearing device to provide a high quality sound to the user where clipping is reduced due to the fast gain reductions and where signal artefacts, such as pumping and switching noise, produced by the fast gain reductions is reduced due to the slow gain reductions. | 10-18-2012 |
Marie Skovgaard, Kobenhavno DK
Patent application number | Description | Published |
---|---|---|
20110293586 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 12-01-2011 |
Marie Skovgaard, Copenhagen Ø DK
Patent application number | Description | Published |
---|---|---|
20120178670 | ACYLATED GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 07-12-2012 |
20150080295 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 03-19-2015 |
Marie Skovgaard, Kobenhavn O DK
Patent application number | Description | Published |
---|---|---|
20110286981 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 11-24-2011 |
20110286982 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 11-24-2011 |
20110293587 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 12-01-2011 |
Marie Skovgaard, Copenhagen O DK
Patent application number | Description | Published |
---|---|---|
20130157935 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 06-20-2013 |
20130157953 | TREATMENT OF CARDIAC CONDITIONS - The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon. | 06-20-2013 |
20140127174 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 05-08-2014 |
20140127175 | GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 05-08-2014 |
Peter M.w. Skovgaard, Birkerod DK
Patent application number | Description | Published |
---|---|---|
20090103874 | OPTICAL FIBER, A FIBER LASER, A FIBER AMPLIFIER AND ARTICLES COMPRISING SUCH ELEMENTS - The invention relates to an optical fiber defining a longitudinal direction, the optical fiber comprising a core having a diameter larger than 10 μm, said core comprises at least two solid segments of different composition, at least one of the segments comprises a photo-sensitive material. The core may be segmented in its cross-sectional direction and/or in its longitudinal direction. The optical fiber may comprise a Bragg grating written in at least one of said solid core segments | 04-23-2009 |
20120236881 | PULSED FIBER LASER - A method and a laser system for generating a pulsed laser signal with a laser signal wavelength and a laser signal repetition rate, the laser system includes a fiber laser unit includes a cladding pumped fiber laser includes a fiber laser light guiding region surrounded by a pump cladding, the fiber laser light guiding region includes at least one active element; at least one pump laser unit for launching a pump signal into the cladding pumped fiber laser, the pump signal unit includes at least one pump diode emitting a signal at a pump signal wavelength; and a modulating unit for modulating the pump signal into a plurality of pump pulses. | 09-20-2012 |
Peter M.w. Skovgaard, Birkerød DK
Patent application number | Description | Published |
---|---|---|
20090202204 | OPTICAL COUPLER, A METHOD OF ITS FABRICATION AND USE - The invention relates to: An optical coupler for coupling light from at least two input fibres into one output fibre. The invention further relates to a method of fabricating and to the use of an optical coupler. The object of the present invention is to provide an optical coupler, which is relatively easy to manufacture. The problem is solved in that the coupler comprises a) an input section comprising at least two input fibres, which are bundled over a bundling-length and having an output end face at one end of the bundling-length; and b) an output section comprising an output fibre comprising a confining region for confining light propagated in said input fibres and a surrounding cladding region and having an input end face; | 08-13-2009 |